The Science Behind Aduhelm, a Controversial New Alzheimer’s Drug | WSJ

Biogen’s Aduhelm is the very first accepted treatment for very early phase Alzheimer’s individuals that might be able to slow the illness. WSJ discusses just how the medication engages with mind cells, and why some physicians aren’t ready to suggest it yet. Image: Jacob Reynolds

Much more from the Wall Street Journal:
Check out WSJ.com: http://www.wsj.com
Visit the WSJ Video Center: https://wsj.com/video

On Facebook: https://www.facebook.com/pg/wsj/videos/
On Twitter: https://twitter.com/WSJ
On Snapchat: https://on.wsj.com/2ratjSM

#Aduhelm #Alzheimers #WSJ